Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

Biosimilars Still Seen As Key Growth Driver Despite Q1 Sales Decline

 
• By Dave Wallace
  
Organon discussed tariffs and biosimilars during its Q1 call (Shutterstock)

More from Biosimilars

More from Earnings